Company profile: Vapogenix
1.1 - Company Overview
Company description
- Provider of clinical-stage non-narcotic topical analgesics for localized pain, including VPX638, a Phase 2 topical for wound pain demonstrating rapid and prolonged relief without systemic side effects; a rapid-acting topical for acute procedural pain on intact skin; and a topical for localized inflammatory pain combining analgesic and anti-inflammatory effects.
Products and services
- Inflammatory Pain Product: A non-narcotic topical analgesic under development for localized inflammatory pain, combining analgesic and anti-inflammatory effects for relief
- Procedural Pain Product: A rapid-onset topical analgesic engineered for intact skin to alleviate acute procedural pain from venipuncture and minor dermatological procedures with fast action
- VPX638: A Phase 2 clinical topical analgesic for wound pain that produces rapid and prolonged relief without systemic side effects
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vapogenix
Adamas Pharma
HQ: United States
Website
- Description: Provider of controlled and extended-release combination therapeutics for infectious diseases and central nervous system disorders, including products for symptomatic treatment of dementia. Offerings include Qelbree for ADHD; Trokendi XR and Oxtellar XR for epilepsy and migraine prevention; and candidates SPN-830 (hypomobility in Parkinson’s disease), SPN-820/821 (treatment-resistant depression), SPN-817 (severe epilepsy).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adamas Pharma company profile →
Sequent Medical
HQ: United States
Website
- Description: Provider of innovative catheter-based neurovascular technologies, including proprietary Microbraid™ technology used to create the WEB™ Aneurysm Embolization System for the treatment of neurovascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequent Medical company profile →
Entheon Biomedical
HQ: Canada
Website
- Description: Provider of biotechnology research and development focused on developing and commercializing safe and effective DMT-based psychedelic therapeutic products to treat addiction and substance use disorders, subject to regulatory approvals; an addiction recovery solution harnessing and optimizing the therapeutic potential of the DMT molecule.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Entheon Biomedical company profile →
Rodin Therapeutics
HQ: United States
Website
- Description: Provider of novel therapeutics for neurological disorders by applying insights of epigenetics, leveraging key epigenetic modulators of CNS function and privileged access to Proteros’ best-in-class structural biology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rodin Therapeutics company profile →
Clairvoyant Therapeutics
HQ: Canada
Website
- Description: Provider of psilocybin-based therapy solutions for Alcohol Use Disorder, including a 24-week Phase 2b clinical trial with synthetic psilocybin and two dosing sessions, a 35-hour therapist training program to support participants, and a therapist adherence monitoring program to monitor adherence to trial protocol and ethics, pursuing a speed-to-market clinical strategy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Clairvoyant Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vapogenix
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vapogenix
2.2 - Growth funds investing in similar companies to Vapogenix
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vapogenix
4.2 - Public trading comparable groups for Vapogenix
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →